This Article Full Text Full Text (PDF) All Versions of this Article: theoncologist.2009-0129v1 14/12/1225    most recent eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Straus, D. J. PubMed PubMed Citation Articles by Straus, D. J.

Lymphoma

The Case for Chemotherapy Only for Localized Hodgkin Lymphoma

Memorial Sloan-Kettering Cancer Center, New York, New York, USA; Weill Medical College, Cornell University, New York, New York, USA

Key Words. Chemotherapy • Localized Hodgkin lymphoma

Correspondence: David J. Straus, M.D., Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA. Telephone: 212-639-8365; Fax: 646-422-2291; e-mail: strausd{at}mskcc.org

Received June 23, 2009; accepted for publication November 3, 2009; first published online in THE ONCOLOGIST Express on December 10, 2009.

Disclosures: David J. Straus: None.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the author or independent peer reviewers.

Although radiation therapy (RT) alone, and more recently in combination with chemotherapy, has been the cornerstone of curative treatment for early-stage Hodgkin lymphoma for >40 years, the late toxicities of this treatment are increasingly being recognized as causes of significant late morbidity and mortality. In recent years, the focus of treatment of early-stage Hodgkin lymphoma has been reductions in the doses and fields of RT and attempts to reduce the amount and the toxicity of chemotherapy. Another approach has been to treat with chemotherapy alone and to eliminate RT entirely unless it is absolutely necessary. This review summarizes the accumulating information on the late side effects of treatment of Hodgkin lymphoma, the results of trials with chemotherapy only, attempts to reduce the toxicity of chemotherapy, and the new role of positron emission tomography in treatment planning.

This article has been cited by other articles:

				G. P. Canellos Is Chemotherapy Alone for Early Hodgkin Lymphoma an Emerging Therapeutic Option? Oncologist, December 1, 2009; 14(12): 1167 - 1168. [Full Text] [PDF]